Format

Send to

Choose Destination
Crit Care. 2011;15(2):129. doi: 10.1186/cc10057. Epub 2011 Mar 9.

Erythropoietin for stroke treatment: dead or alive?

Author information

1
Department of Neurology, University Hospital Münster, Albert-Schweitzer-Straße 33, 48149 Münster, Germany. minnerup@uni-muenster.de

Abstract

Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues investigated the effect of EPO in stroke patients on both clinical outcome and EPC stimulation. Although beneficial effects of EPO were observed, several issues regarding EPO's suitability as a stroke drug remain.

PMID:
21418552
PMCID:
PMC3219325
DOI:
10.1186/cc10057
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center